The burgeoning landscape of treatment for obesity and type 2 metabolic disorder is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant variations in their pharmacological profiles and clinical study results are emerging. Retatrutide

Showing promise in the field of obesity therapy, retatrutide presents a distinct strategy. Different from many current medications, retatrutide operates as a twin agonist, simultaneously engaging both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) receptors. The dual engagement encourages various helpful effects, like impr